Baseline Characteristics
Pembro 2 Q3W
n = 344
Pembro 10 Q3W
n = 346
Docetaxel
n = 343
Age, median (range), years
63 (29-82)
63 (20-88)
62 (33-82)
Male, %
62
62
61
ECOG PS,
a
%
0
1
33
67
35
65
34
65
Smoking status, %
Former/current
Never
Unknown
81
18
1
82
17
<1
78
20
2
PD-L1 TPS, %
≥50%
1-49%
40
60
44
56
44
56
Prior therapy, %
Adjuvant
Neoadjuvant
Prior lines, advanced
disease
1
≥2
2
<1
71
27
2
<1
68
20
1
0
69
22
a
1 patient had unknown ECOG PS. 5/6 patients with ECOG PS ≥2
during screening resolved to ≤1 by treatment assignment.
Analysis cut-off date: September 30, 2015.
Herbst RS et al.
Lancet
2016; 387: 1540–1550 (and online appendix).
